Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YH 12852

Next Previous
Drug Profile

YH 12852

Alternative Names: PCS-12852; YH-12852

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yuhan
  • Developer Processa Pharmaceuticals; Seoul National University Hospital; Yuhan
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Peristaltic stimulants; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic gastroparesis; Dyspepsia; Gastroparesis
  • Phase I/II Constipation
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 17 Jun 2025 Processa Pharmaceuticals signed binding term sheet with Intact Therapeutics for the exclusive option to license YH 12852
  • 14 Mar 2024 YH 12852 is available for licensing as of 14 Mar 2024 (Evoke Pharma SEC filing, March 2024)
  • 06 Oct 2022 Processa Pharmaceuticals completed the phase II MOMENTUM trial in Gastroparesis and Diabetic gastroparesis in USA (PO) (NCT05270460)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top